NYSE · Healthcare
DANAHER CORP /DE/ (DHR)
As-reported financials and recent SEC filings for DANAHER CORP /DE/, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$24.57B
Net income
$3.61B
Net margin
14.7%
Diluted EPS
$5.05
ROE
6.9%
P/E (TTM)
35.0×
Market cap
$127.47B
Debt / equity
0.4×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $24.57B | $23.88B | $23.89B | $26.64B | $24.80B |
| Gross profit | $14.52B | $14.21B | $14.03B | $16.19B | $15.24B |
| Operating income | $4.69B | $4.86B | $5.20B | $7.54B | $6.38B |
| Net income | $3.61B | $3.90B | $4.76B | $7.21B | $6.43B |
| Diluted EPS | $5.05 | $5.29 | $6.38 | $9.66 | $8.61 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
S-82026-06-09
View on EDGAR →S-82026-06-09
View on EDGAR →8-K2026-06-03
View on EDGAR →42026-05-19
View on EDGAR →42026-05-19
View on EDGAR →42026-05-19
View on EDGAR →42026-05-19
View on EDGAR →42026-05-19
View on EDGAR →Go deeper on DHR
Search DANAHER CORP /DE/’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.